JW THERAP-B (02126) saw its shares surge over 9% during intraday trading. At the time of writing, the stock was up 4.55% to HK$3.22, with a turnover of HK$3.73 million.

According to an announcement by JW THERAP-B, on December 7, the company confirmed that Breyanzi® (relmacabtagene autoleucel injection), its first China-developed and approved Class 1 innovative CAR-T therapy, has been successfully included in the inaugural National Reimbursement Drug List for Commercial Health Insurance Innovation Products.

Breyanzi® is currently the only CAR-T therapy in China approved for three non-Hodgkin lymphoma indications, including relapsed or refractory large B-cell lymphoma, relapsed or refractory follicular lymphoma, and relapsed or refractory mantle cell lymphoma. Prior to its inclusion in the national reimbursement list, Breyanzi® had already been covered by over 100 inclusive insurance plans and nearly 100 million-yuan medical insurance policies due to its demonstrated clinical value. The therapy has undergone extensive clinical practice and real-world studies, validating its efficacy among Chinese patients.